You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDihydrocodeine
Accession NumberDB01551
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionDihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911. [Wikipedia]
Structure
Thumb
Synonyms
DHC
Remedacen
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CodidolNot Available
ContugesicNot Available
DehaceNot Available
DF-118 ForteNot Available
DicogesicNot Available
HydrocodinNot Available
RemedacenNot Available
Brand mixtures
NameLabellerIngredients
Acetaminophen, Caffeine and Dihydrocodeine BitartrateLarken Laboratories Inc.
Acetaminophen, Caffeine, Dihydrocodeine BitartrateXspire Pharma Llc
Aspirin, Caffeine, and Dihydrocodeine BitartrateCaraco Pharmaceutical Laboratories, Ltd
Centussin DhcCenturion Labs, Llc
Dihydrocodeine Bitartrate, Acetaminophen and CaffeinePhysicians Total Care, Inc.
J-cof DhcJay Mac Pharmaceuticals
J-max DhcJay Mac Pharmaceuticals
Poly Hist DhcPoly Pharmaceuticals, Inc.
Poly-tussin EXPoly Pharmaceuticals, Inc.
SynalgosCaraco Pharma Inc.
TrezixWra Ser Llc
Salts
Name/CASStructureProperties
Dihydrocodeine bitartrate
Thumb
  • InChI Key: ZGSZBVAEVPSPFM-HYTSPMEMSA-N
  • Monoisotopic Mass: 451.184231531
  • Average Mass: 451.467
DBSALT000048
Dihydrocodeine hydrobromide
ThumbNot applicableDBSALT000049
Dihydrocodeine hydrochloride
36418-29-8
Thumb
  • InChI Key: VMZXMTVGOAQUEN-FFHNEAJVSA-N
  • Monoisotopic Mass: 337.144471346
  • Average Mass: 337.841
DBSALT000050
Dihydrocodeine hydroiodide
5965-15-1
Thumb
  • InChI Key: QXBJOHDQNJOLNA-PKHFJCIDNA-N
  • Monoisotopic Mass: 429.080087059
  • Average Mass: 429.2925
DBSALT000051
Dihydrocodeine methyliodide
ThumbNot applicableDBSALT000052
Dihydrocodeine phosphate
Thumb
  • InChI Key: HFBYLYCMISIEMM-FFHNEAJVSA-N
  • Monoisotopic Mass: 399.144688703
  • Average Mass: 399.3753
DBSALT000053
Dihydrocodeine sulfate
ThumbNot applicableDBSALT000054
Dihydrocodeine tartrate
ThumbNot applicableDBSALT000055
Categories
UNIIN9I9HDB855
CAS number125-28-0
WeightAverage: 301.3801
Monoisotopic: 301.167793607
Chemical FormulaC18H23NO3
InChI KeyRBOXVHNMENFORY-DNJOTXNNSA-N
InChI
InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-ol
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC[C@@H]2O
Pharmacology
IndicationDihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain [2]. It can also be used to treat chronic pain [1], breathlessness and coughing. In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014322/]
Structured Indications
PharmacodynamicsPossible opioid related side effects include, but are not limited to, drowsiness, nausea, headache, dry mouth, constipation, difficulty passing urine, and mild euphoria.
Mechanism of actionDihydrocodeine is metabolized to dihydromorphine -- a highly active metabolite with a high affinity for mu opioid receptors. [3]
Related Articles
AbsorptionBioavailability is low (approximately 20%) if administered orally. This may be due to poor gastrointestinal absorption. It is also likely due to pre-systemic metabolism by the liver and intestinal wall. [2] The AUCs after oral and intravenous administration are similar (3203ug/l/h and 3401ug/l/h, respectively). [2] Time to peak values are 1.6 and 1.8hours for a 30mg and 60mg dose, respectively. The concentrations achieved were 71.8 ug/1 and 146 ug/1, respectively. [2]
Volume of distribution

The disposition of dihydrocodeine is described as a two compartment model. 2

Protein bindingNot Available
Metabolism

Metabolized in the liver by CYP 2D6 into an active metabolite, dihydromorphine, and by CYP 3A4 into secondary primary metabolite, nordihydrocodeine. A third primary metabolite is dihydrocodeine-6-glucuronide. [1] The time for mean peak concentration in acid metabolites is 1.76h and 1.98h for a 30 and 60mg dose, respectively. The concentrations achieved were 563 ug/1 and 1476 ug/1, respectively. [2]

Route of eliminationRenal elimination and urinary excretion. [1]
Half life4h
Clearance

Plasma clearance is approximately 300ml/min. 2

The pharmacokinetics of dihydrocodeine and active metabolite dihydromorphine have been reported to be linear. 1

The decline in plasma dihydrocodeine concentrations after intravenous administration has been described as bi-exponential, with a sleep decline in the initial 2h following administration, followed by a mono-exponential decline thereafter. Clearance was not dose dependent. 2

ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Dihydrocodeine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydrocodeine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dihydrocodeine.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Dihydrocodeine.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydrocodeine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Dihydrocodeine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dihydrocodeine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydrocodeine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dihydrocodeine.Approved
AprepitantThe serum concentration of Dihydrocodeine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydrocodeine.Approved, Investigational
ArtemetherThe metabolism of Dihydrocodeine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Asenapine.Approved
AtazanavirThe metabolism of Dihydrocodeine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Dihydrocodeine can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydrocodeine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dihydrocodeine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azaperone.Vet Approved
AzelastineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydrocodeine.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydrocodeine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydrocodeine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dihydrocodeine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Dihydrocodeine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Dihydrocodeine can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydrocodeine.Approved
BL-1020BL-1020 may increase the hypotensive activities of Dihydrocodeine.Investigational
BoceprevirThe metabolism of Dihydrocodeine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Dihydrocodeine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dihydrocodeine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydrocodeine.Approved, Investigational
BuprenorphineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Dihydrocodeine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydrocodeine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydrocodeine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydrocodeine.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Dihydrocodeine.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Canrenone.Investigational
CarbamazepineThe metabolism of Dihydrocodeine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dihydrocodeine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Dihydrocodeine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Dihydrocodeine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dihydrocodeine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dihydrocodeine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydrocodeine.Approved
ChloroquineThe metabolism of Dihydrocodeine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydrocodeine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Dihydrocodeine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Dihydrocodeine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydrocodeine.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Dihydrocodeine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cicletanine.Investigational
CimetidineThe metabolism of Dihydrocodeine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Dihydrocodeine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydrocodeine.Approved, Vet Approved
CitalopramThe metabolism of Dihydrocodeine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Dihydrocodeine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Dihydrocodeine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clidinium.Approved
ClobazamThe metabolism of Dihydrocodeine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Dihydrocodeine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydrocodeine.Approved, Illicit
ClotrimazoleThe metabolism of Dihydrocodeine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Dihydrocodeine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Dihydrocodeine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Dihydrocodeine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydrocodeine.Approved, Illicit
ConivaptanThe serum concentration of Dihydrocodeine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Dihydrocodeine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydrocodeine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydrocodeine.Approved
CyclosporineThe metabolism of Dihydrocodeine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydrocodeine.Approved
DapoxetineDihydrocodeine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Dihydrocodeine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Dihydrocodeine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dihydrocodeine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Dihydrocodeine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dihydrocodeine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydrocodeine.Approved
DesipramineThe metabolism of Dihydrocodeine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.Approved
DesvenlafaxineDihydrocodeine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydrocodeine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydrocodeine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dihydrocodeine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydrocodeine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dihydrocodeine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydrocodeine.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydrocodeine.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Difenoxin.Approved, Illicit
DihydroergotamineThe metabolism of Dihydrocodeine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydrocodeine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Dihydrocodeine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Dihydrocodeine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydrocodeine.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doxepin.Approved
DoxycyclineThe metabolism of Dihydrocodeine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DronedaroneThe metabolism of Dihydrocodeine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dihydrocodeine.Experimental, Illicit
DuloxetineThe metabolism of Dihydrocodeine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydrocodeine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dihydrocodeine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Dihydrocodeine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Efonidipine.Approved
EliglustatThe metabolism of Dihydrocodeine can be decreased when combined with Eliglustat.Approved
EluxadolineDihydrocodeine may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dihydrocodeine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Dihydrocodeine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Eplerenone.Approved
ErythromycinThe metabolism of Dihydrocodeine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramDihydrocodeine may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Dihydrocodeine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydrocodeine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydrocodeine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etacrynic acid.Approved
EthanolDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydrocodeine.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dihydrocodeine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dihydrocodeine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydrocodeine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydrocodeine.Approved
EtoperidoneDihydrocodeine may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dihydrocodeine.Illicit, Vet Approved
EtravirineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dihydrocodeine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydrocodeine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydrocodeine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dihydrocodeine.Approved, Illicit
FluoxetineThe metabolism of Dihydrocodeine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydrocodeine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydrocodeine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydrocodeine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Dihydrocodeine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Dihydrocodeine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dihydrocodeine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Dihydrocodeine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dihydrocodeine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydrocodeine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dihydrocodeine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dihydrocodeine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dihydrocodeine.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dihydrocodeine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dihydrocodeine.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Dihydrocodeine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydrocodeine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dihydrocodeine.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydrocodeine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydrocodeine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydrocodeine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydrocodeine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Dihydrocodeine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydrocodeine.Approved
IdelalisibThe serum concentration of Dihydrocodeine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iloperidone.Approved
ImatinibThe metabolism of Dihydrocodeine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Dihydrocodeine can be decreased when combined with Imipramine.Approved
IndalpineDihydrocodeine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Indapamide.Approved
IndinavirThe metabolism of Dihydrocodeine can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydrocodeine.Approved
IsavuconazoniumThe metabolism of Dihydrocodeine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dihydrocodeine.Approved, Vet Approved
IsoniazidThe metabolism of Dihydrocodeine can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Isosorbide.Approved
IsradipineThe metabolism of Dihydrocodeine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dihydrocodeine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydrocodeine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dihydrocodeine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydrocodeine.Approved
LevomilnacipranDihydrocodeine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydrocodeine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydrocodeine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dihydrocodeine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydrocodeine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Dihydrocodeine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydrocodeine.Approved
LorcaserinThe metabolism of Dihydrocodeine can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Dihydrocodeine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydrocodeine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Dihydrocodeine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Dihydrocodeine can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Dihydrocodeine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydrocodeine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dihydrocodeine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Dihydrocodeine.Investigational
MephentermineMephentermine may increase the analgesic activities of Dihydrocodeine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydrocodeine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydrocodeine.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dihydrocodeine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metaxalone.Approved
MethadoneThe metabolism of Dihydrocodeine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dihydrocodeine.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydrocodeine.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydrocodeine.Approved
MethotrimeprazineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydrocodeine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Dihydrocodeine.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydrocodeine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydrocodeine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metolazone.Approved
MetoprololThe metabolism of Dihydrocodeine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineDihydrocodeine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydrocodeine.Approved, Illicit
MifepristoneThe serum concentration of Dihydrocodeine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranDihydrocodeine may increase the serotonergic activities of Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Investigational
MirabegronThe metabolism of Dihydrocodeine can be decreased when combined with Mirabegron.Approved
MirtazapineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Dihydrocodeine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit
ModafinilThe serum concentration of Dihydrocodeine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Dihydrocodeine.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydrocodeine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Dihydrocodeine.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Investigational
NafcillinThe serum concentration of Dihydrocodeine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Dihydrocodeine.Approved
NaltrexoneThe therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Dihydrocodeine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dihydrocodeine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dihydrocodeine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dihydrocodeine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Dihydrocodeine can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Dihydrocodeine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Dihydrocodeine.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydrocodeine.Approved, Investigational
OlaparibThe metabolism of Dihydrocodeine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydrocodeine.Approved
OpiumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Opium.Approved, Illicit
OrphenadrineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Dihydrocodeine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydrocodeine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydrocodeine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydrocodeine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydrocodeine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydrocodeine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dihydrocodeine.Approved
PalbociclibThe serum concentration of Dihydrocodeine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydrocodeine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydrocodeine.Approved
PanobinostatThe serum concentration of Dihydrocodeine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Dihydrocodeine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Dihydrocodeine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.Approved
PentazocinePentazocine may decrease the analgesic activities of Dihydrocodeine.Approved, Vet Approved
PentobarbitalThe metabolism of Dihydrocodeine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydrocodeine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dihydrocodeine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydrocodeine.Approved
PhenobarbitalThe metabolism of Dihydrocodeine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
PhenytoinThe metabolism of Dihydrocodeine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydrocodeine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydrocodeine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydrocodeine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleDihydrocodeine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydrocodeine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dihydrocodeine.Approved
PrimidoneThe metabolism of Dihydrocodeine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dihydrocodeine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydrocodeine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydrocodeine.Approved
PromazineThe metabolism of Dihydrocodeine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydrocodeine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydrocodeine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Dihydrocodeine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dihydrocodeine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydrocodeine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Dihydrocodeine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydrocodeine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quinethazone.Approved
QuinidineQuinidine may decrease the analgesic activities of Dihydrocodeine.Approved
QuinineThe metabolism of Dihydrocodeine can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ramelteon.Approved, Investigational
RamosetronDihydrocodeine may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Dihydrocodeine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydrocodeine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydrocodeine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydrocodeine.Approved
RifabutinThe metabolism of Dihydrocodeine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dihydrocodeine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dihydrocodeine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydrocodeine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Dihydrocodeine.Investigational
RitonavirThe metabolism of Dihydrocodeine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Dihydrocodeine can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Romifidine.Vet Approved
RopiniroleDihydrocodeine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydrocodeine.Approved
RotigotineDihydrocodeine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydrocodeine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sage 547.Investigational
SaquinavirThe metabolism of Dihydrocodeine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydrocodeine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydrocodeine.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Dihydrocodeine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydrocodeine.Approved, Vet Approved
SildenafilThe metabolism of Dihydrocodeine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dihydrocodeine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dihydrocodeine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydrocodeine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Dihydrocodeine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Dihydrocodeine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dihydrocodeine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine.Approved, Investigational
SulfisoxazoleThe metabolism of Dihydrocodeine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydrocodeine.Approved
SuvorexantDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Dihydrocodeine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Dihydrocodeine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydrocodeine.Approved
TerbinafineThe metabolism of Dihydrocodeine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrodotoxin.Investigational
ThalidomideDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydrocodeine.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dihydrocodeine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydrocodeine.Approved, Vet Approved
ThioridazineThe metabolism of Dihydrocodeine can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Dihydrocodeine can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dihydrocodeine.Approved
TipranavirThe metabolism of Dihydrocodeine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Dihydrocodeine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tolcapone.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydrocodeine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydrocodeine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Dihydrocodeine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydrocodeine.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydrocodeine.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydrocodeine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dihydrocodeine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydrocodeine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydrocodeine.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydrocodeine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dihydrocodeine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydrocodeine.Approved
Uc1010The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Dihydrocodeine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dihydrocodeine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydrocodeine.Approved
VenlafaxineThe metabolism of Dihydrocodeine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Dihydrocodeine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydrocodeine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ziconotide.Approved
ZimelidineDihydrocodeine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Dihydrocodeine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zolazepam.Vet Approved
ZolpidemDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dihydrocodeine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Alcohol may enhance CNS depressant effects
References
Synthesis Reference

Igor Likhotvorik, “Preparation of dihydrocodeine from codeine.” U.S. Patent US06887999, issued May 03, 2005.

US06887999
General References
  1. Ammon S, Hofmann U, Griese EU, Gugeler N, Mikus G: Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22. [PubMed:10510141 ]
  2. Rowell FJ, Seymour RA, Rawlins MD: Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. Eur J Clin Pharmacol. 1983;25(3):419-24. [PubMed:6628531 ]
  3. Schmidt H, Vormfelde SV, Walchner-Bonjean M, Klinder K, Freudenthaler S, Gleiter CH, Gundert-Remy U, Skopp G, Aderjan R, Fuhr U: The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106. [PubMed:12665158 ]
External Links
ATC CodesN02AA58N02AA08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9942
Blood Brain Barrier+0.9974
Caco-2 permeable+0.8388
P-glycoprotein substrateSubstrate0.8754
P-glycoprotein inhibitor IInhibitor0.5937
P-glycoprotein inhibitor IINon-inhibitor0.9652
Renal organic cation transporterInhibitor0.5676
CYP450 2C9 substrateNon-substrate0.831
CYP450 2D6 substrateSubstrate0.9143
CYP450 3A4 substrateSubstrate0.7941
CYP450 1A2 substrateNon-inhibitor0.8554
CYP450 2C9 inhibitorNon-inhibitor0.9074
CYP450 2D6 inhibitorInhibitor0.7395
CYP450 2C19 inhibitorNon-inhibitor0.7689
CYP450 3A4 inhibitorNon-inhibitor0.8114
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.957
Ames testNon AMES toxic0.8074
CarcinogenicityNon-carcinogens0.9522
BiodegradationNot ready biodegradable0.9857
Rat acute toxicity2.9382 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9058
hERG inhibition (predictor II)Non-inhibitor0.8246
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral
LiquidOral
TabletOral
SyrupOral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point112.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility2.38 mg/mLALOGPS
logP1.58ALOGPS
logP1.55ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)14.15ChemAxon
pKa (Strongest Basic)9.33ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity83.64 m3·mol-1ChemAxon
Polarizability32.82 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23